Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BAC-free latanoprost + timolol versus Xalacom in open-angle glaucoma or ocular hypertension
2022-001178-70Phase 3Completed
- Sponsor
- actrevo
- Start
- Dec 2022
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of latanoprost and timolol in open-angle glaucoma (OAG) and ocular hypertension (2 arms), sponsored by actrevo. Started Dec 2022; status: completed.
02
Drugs
latanoprosttimolol
03
Conditions
open-angle glaucoma (OAG)ocular hypertension
Beyond the preview
Go deeper on 2022-001178-70.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-001178-70.